Stereochemistry | RACEMIC |
Molecular Formula | C11H12N2O2 |
Molecular Weight | 204.2252 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C1=NC(=O)C(O1)C2=CC=CC=C2
InChI
InChIKey=JJSHYECKYLDYAR-UHFFFAOYSA-N
InChI=1S/C11H12N2O2/c1-13(2)11-12-10(14)9(15-11)8-6-4-3-5-7-8/h3-7,9H,1-2H3
Molecular Formula | C11H12N2O2 |
Molecular Weight | 204.2252 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Thozalinone (Stimsen) has been used as an antidepressant in Europe and has also been trialed as an anorectic. It acts via inducing the release of norepinephrine and dopamine as with its analogues pemoline and aminorex. Thozalinone has been shown to possess some pharmacologic actions similar to those of amphetamine and imipramine, but with important differences. It is less toxic than amphetamine, and its margin of safety in mice is greater. The stimulant action does not progress to tremors or convulsions as the dosage is increased. The anorexigenic activity of thozalinone is more pronounced and longer lasting than that of amphetamine. There is no evidence of the development of tolerance. The cardiovascular side effects of thozalinone are minimal, and analeptic actions are absent.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Thozalinone (7.5-960 mg/kg orally) increased locomotor activity, preening, and
searching movements in mice and rats, and increased the sensitivity to auditory and tactile stimuli (hyperesthesia) in mice. Rats treated with thozalinone (2-64 mg/kg orally) showed hyperesthesia, alertness, and increased exploratory behavior.
Route of Administration:
Oral